- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01144026
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects (THYMON-10001)
Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HIV-1 Tat protein, a virally encoded toxin, is secreted by HIV-1 infected cells and acts on uninfected cells, rendering them permissive for HIV-1 replication. HIV-1 Tat enhances chronic viral replication and induces immune suppression. Antibodies to Tat inhibit this Tat-mediated transcellular activation in vitro and minimize chronic plasma viremia. HIV-1 Tat activities can be blocked in vitro and in vivo by anti-Tat antibodies.
The Thymon Universal Tat Immunogen (TUTI-16) is a fully synthetic, self-adjuvanting lipopeptide vaccine that is water soluble and administered by subcutaneous injection. In preclinical studies, a priming dose and a three week boost in rats induced a high titer antibody response to the eight known distinct epitope variants of HIV-1 Tat protein. These antibodies block the function of the HIV-1 Tat protein (toxin), which is essential to the maintenance of chronic HIV-1 viremia. Therefore, TUTI-16 has potential as a therapeutic vaccine for HIV-1 in humans.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10019
- Clinilabs
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and Females
- Age ≥18 and ≤50 years at Screening
- HIV negative healthy subjects or HIV-1 seropositive subjects on effective ART for >2 months (undetectable HIV plasma viremia), viral set point before ART >3,000
- CD4+ T-cell count ≥ 500/mm3.
Exclusion Criteria:
- Pregnant/nursing females
- Positive for HBV or HCV
- Acute Herpetic event
- Any clinically significant out-of range laboratory value
- Routine or PRN consumption of immune suppressive medications that the subject is unable or unwilling to discontinue during the study
- Participation in another investigational drug/vaccine study within 30 days preceding the first injection of investigational agent in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TUTI-16 (0.2mg)
Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
|
Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
|
Experimental: TUTI-16 (1.0 mg)
Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
|
Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-Tat Antibody Titer
Time Frame: 5 weeks
|
ELISA based chemiluminescent assay to determine the anti-Tat antibody response
|
5 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mardik Donikyan, MD, Clinilabs, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- THYMON-10001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on TUTI-16 (0.2mg)
-
Thymon, LLCCompletedHIV InfectionsUnited States
-
Thymon, LLCCompletedHIV InfectionsUnited States
-
Hanmi Pharmaceutical Company LimitedCompletedBenign Prostatic Hyperplasia
-
Zhejiang Cancer HospitalRecruiting
-
VA Office of Research and DevelopmentNational Institutes of Health (NIH)CompletedParalysis | Spinal Cord Injury | Tetraplegia | ParaplegiaUnited States
-
Radboud University Medical CenterCompleted
-
Beat AML, LLCRecruitingPreviously Untreated Acute Myeloid LeukemiaUnited States
-
Centocor Ortho Biotech Services, L.L.C.Completed
-
Case Western Reserve UniversityNational Institutes of Health (NIH); US Department of Veterans AffairsRecruitingStroke | Paralysis | Spinal Cord Injuries | Tetraplegia | ParaplegiaUnited States
-
Janssen Research & Development, LLCCompleted